Point72 Asset Management
MYGN icon

Point72 Asset Management’s Myriad Genetics MYGN Stock Holding History

Point72 Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-400,000
Closed -$2.12M – 2555
2025
Q2 		$2.12M Buy
+400,000
New +$2.36M ﹤0.01% 1286

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management's MYGN Position: Q2 2026 in Review

Point72 Asset Management reduced its Myriad Genetics (MYGN) stake by 75% in Q2 2026, selling an estimated $3.26M and leaving 238,776 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2633.

Point72 Asset Management first reported a position in MYGN in Q4 2014 and has held it in 33 quarters since. The position peaked at $31.2M in Q2 2018. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Point72 Asset Management held 238,776 shares of Myriad Genetics worth $1.36M as of Q2 2026.
  • Point72 Asset Management sold 719,125 Myriad Genetics shares in Q2 2026, an estimated $3.26M.
  • Myriad Genetics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #2633 holding.
  • Point72 Asset Management first reported a position in Myriad Genetics in Q4 2014 and has held it in 33 quarters since.
  • Point72 Asset Management's Myriad Genetics position peaked at $31.2M in Q2 2018.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.